Barinthus Biotherapeutics plc. financial data

Symbol
BRNS on Nasdaq
Industry
Pharmaceutical Preparations
Location
Unit 6 10, Zeus Building, Rutherford Avenue, Harwell, Didcot, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Vaccitech plc (to 10/5/2023), Vaccitech Ltd (to 3/23/2021)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.01K % -27.9%
Debt-to-equity 16.9 % +27.2%
Return On Equity -34.3 % +1.35%
Return On Assets -29.3 % +4.41%
Operating Margin -431 % +64.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40.2M shares +4.31%
Common Stock, Shares, Outstanding 39.5M shares +2.58%
Entity Public Float 79.4M USD -52.1%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39.4M shares +2.3%
Weighted Average Number of Shares Outstanding, Diluted 39.4M shares +2.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 15M USD +106%
Research and Development Expense 40.3M USD -20.5%
General and Administrative Expense 40.2M USD +1296%
Operating Income (Loss) -64.6M USD +27.5%
Nonoperating Income (Expense) 5.82M USD -22.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -58.7M USD +28%
Income Tax Expense (Benefit) -867K USD +79.7%
Net Income (Loss) Attributable to Parent -57.8M USD +25.1%
Earnings Per Share, Basic -1.48 USD/shares +27.5%
Earnings Per Share, Diluted -1.48 USD/shares +27.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 142M USD -26.9%
Accounts Receivable, after Allowance for Credit Loss, Current 172K USD -99%
Other Assets, Current 464K USD +30.7%
Assets, Current 135M USD -21.3%
Property, Plant and Equipment, Net 10.7M USD -12.6%
Operating Lease, Right-of-Use Asset 7.44M USD -0.4%
Intangible Assets, Net (Excluding Goodwill) 22.7M USD -12.2%
Goodwill 12.2M USD 0%
Assets 189M USD -18%
Accounts Payable, Current 3.08M USD -40.2%
Contract with Customer, Liability, Current 111K USD -43.4%
Liabilities, Current 15.1M USD -18.8%
Deferred Income Tax Liabilities, Net 457K USD
Operating Lease, Liability, Noncurrent 10.7M USD -4.63%
Other Liabilities, Noncurrent 1.41M USD +10%
Liabilities 29.2M USD -15%
Retained Earnings (Accumulated Deficit) -217M USD -36.3%
Stockholders' Equity Attributable to Parent 159M USD -18.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 159M USD -18.5%
Liabilities and Equity 189M USD -18%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.8M USD -272%
Net Cash Provided by (Used in) Financing Activities 503K USD -70.2%
Net Cash Provided by (Used in) Investing Activities -308K USD +87.7%
Common Stock, Shares Authorized 39.5M shares +2.58%
Common Stock, Shares, Issued 39.5M shares +2.58%
Common Stock, Par or Stated Value Per Share 0 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1M USD -296%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 106M USD -33.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 25.1M USD +82.8%
Deferred Tax Assets, Gross 36.2M USD +60%
Operating Lease, Liability 12.7M USD -0.27%
Depreciation 2.7M USD +42.1%
Payments to Acquire Property, Plant, and Equipment 308K USD -87.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -42.3M USD +26.1%
Lessee, Operating Lease, Liability, to be Paid 16.8M USD -4.4%
Property, Plant and Equipment, Gross 15.5M USD +67.1%
Operating Lease, Liability, Current 1.99M USD +32.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.02M USD +6.83%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.99M USD +14.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -37K USD +92.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.1M USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.04M USD +6.8%
Deferred Tax Assets, Operating Loss Carryforwards 23.6M USD +137%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.07M USD +6.76%
Operating Lease, Payments 346K USD +57.3%
Additional Paid in Capital 392M USD +1.6%
Amortization of Intangible Assets 3.2M USD 0%
Depreciation, Depletion and Amortization 1.43M USD +17.1%
Deferred Tax Assets, Net of Valuation Allowance 11.2M USD +25.1%
Share-based Payment Arrangement, Expense 4.74M USD -24.9%
Interest Expense 12K USD